Amneal Pharmaceuticals acquires Kashiv BioSciences to build a fully integrated biosimilars platform, strengthening pipeline capabilities and driving long-term growth in a rapidly expanding market.
Written By: Pharmacally Medical News Desk
Amneal Pharmaceuticals, Inc. has entered into a definitive agreement to acquire 100% of Kashiv BioSciences, LLC in a transaction designed to significantly strengthen its position in the global biosimilars market.
The deal includes an upfront consideration of $375 million in cash and $375 million in equity payable at closing, along with up to $350 million in additional payments contingent on the achievement of regulatory milestones.
The structure also includes potential royalty payments tied to commercial performance and includes funding support for Kashiv’s operations through the closing period. The transaction is expected to close in the second half of 2026, subject to shareholder approval, regulatory clearances, and customary closing conditions.
Strategically, the acquisition positions Amneal to capitalize on a significant upcoming market opportunity, as more than $300 billion worth of biologic products are expected to lose exclusivity over the next decade.
With biosimilar adoption accelerating across healthcare systems, the combination of Kashiv’s research, development, and manufacturing capabilities with Amneal’s commercial scale creates a fully integrated global platform.
This integration is expected to enhance speed to market, enable parallel development and commercialization, and establish a strong foundation for consistent biosimilar launches.
The combined entity is expected to build a robust pipeline, with projections indicating more than 12 commercial biosimilars and over 20 additional products in development by 2030.
This expansion not only strengthens Amneal’s competitive positioning but also diversifies its growth beyond its existing segments, extending its long-term growth trajectory into the next decade. Kashiv’s specialized expertise in biosimilars complements Amneal’s established market access and distribution capabilities, resulting in a strategically aligned and scalable platform.
From a financial perspective, the transaction is expected to generate between $400 million and $500 million in synergies, driven by operational efficiencies, the elimination of future milestone and royalty obligations through 2030, and additional tax and structural benefits.
The deal is structured with a balanced mix of cash and equity to maintain financial flexibility, with minimal impact on leverage. Amneal has outlined a clear path to reducing net leverage to below 3x by 2028, reinforcing its commitment to disciplined capital management while pursuing growth.
Overall, the acquisition represents a transformational step for Amneal, enabling it to establish leadership in a rapidly expanding biosimilars market.
Chirag Patel & Chintu Patel Co-Founder and Co-Chief Executive Officer of Amneal emphasize that the acquisition positions Amneal Pharmaceuticals, Inc. as a fully integrated global biosimilars leader, combining Kashiv’s R&D and manufacturing strengths with Amneal’s commercial capabilities. The deal is viewed as a strategic step to capitalize on the growing biosimilars market, accelerate product launches, expand access to affordable biologics, and drive long-term growth and value creation.
Sandeep Athalye Chief Executive Officer at Kashiv highlights the acquisition as a natural extension of a long-standing partnership, bringing together complementary capabilities at a key moment for the biosimilars market. The focus is on advancing the pipeline, building on a strong track record of approvals, and improving patient access to high-quality, life-changing therapies through the combined platform.
By combining complementary capabilities and leveraging a long-standing collaboration between the two companies, the transaction is expected to enhance access to affordable biologic medicines while delivering sustained growth and long-term value creation.
Reference